UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 28, 2015

Anavex Life Sciences Corp.
(Exact name of registrant as specified in its charter)

Nevada 000-51652 20-8365999
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

51 West 52 nd Street, 7 th Floor, New York, NY USA 10019
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code 1-844-689-3939

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

- 2 -

Item 7.01           Regulation FD Disclosure.

On September 28, 2015, Anavex Life Sciences Corp., a Nevada corporation (the “ Company ”), decided to disclose to its stockholders, and is filing with this report, as Exhibit 99.1, the consolidated balance sheet of the Company as of September 15, 2015.

The information in this Form 8-K shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01           Financial Statements and Exhibits.

(d) Exhibits
99.1 Consolidated Balance Sheet as of September 15, 2015 of Anavex Life Sciences Corp.

- 3 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   
  ANAVEX LIFE SCIENCES CORP.
   
  /s/ Christopher Missling
  Name: Christopher Missling, PhD
                     Chief Executive Officer
   
  Date: September 28, 2015

ANAVEX LIFE SCIENCES CORP.
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
September 15, 2015 and September 30, 2014
(Unaudited)

ASSETS

    September 15,     September 30,  
    2015     2014  
Current            
   Cash $  13,101,846   $  7,262,138  
   Prepaid expenses   79,321     89,117  
Total current assets   13,181,167     7,351,255  
Equipment   1,501     2,247  
Total assets $  13,182,668   $  7,353,502  

LIABILITIES

Current            
   Accounts payable and accrued liabilities $  1,016,369   $  1,249,084  
   Promissory notes payable   92,516     192,065  
Total current liabilities   1,108,885     1,441,149  
Non-interest bearing liabilities   436     5,719,727  
Total liabilities   1,109,321     7,160,876  

STOCKHOLDERS' EQUITY

Capital stock            
   Authorized:            
       400,000,000 common shares, par value $0.001 per share            
   Issued and outstanding:            
       124,503,297 common shares (September 30, 2014 - 47,200,237)   124,503     47,201  
Additional paid-in capital   72,949,380     52,078,750  
Common stock to be issued   777,415     640,000  
Accumulated deficit   (61,777,951 )   (52,573,325 )
Total stockholders' equity   12,073,347     192,626  
Total liabilities and stockholders' equity $  13,182,668   $  7,353,502